Expert Discusses JCAR017 CAR T-Cell Therapy in Non-Hodgkin Lymphoma – OncLive
OncLive |
Expert Discusses JCAR017 CAR T-Cell Therapy in Non-Hodgkin Lymphoma
OncLive “This is an important, exciting, and possibly new paradigm for treating lymphoma but the data are still early,” explained Leo I. Gordon MD, director of the Lymphoma Program in the Division of Hematology/Oncology at the Northwestern University Feinberg … ‘Extraordinary’ new cancer drug appears to cure a third of terminal …The Independent BioNews – Remission in one-third of terminal lymphoma patients …BioNews Cancer Cure News 2017: New Gene Therapy Treatment May …Christian Post Seeking Alpha all 4 news articles » |
Globalnews.ca |
Could you save his life? Edmonton boy needs to find stem cell match
Globalnews.ca Another stem cell swab event is taking place on Thursday with the hopes of finding a match for an eight-year-old Edmonton boy with leukemia. In November, Brady Mishio’s dad took him to the hospital because he thought he had the flu. “Quickly they did … |
Wall Street Pit |
Induced Pluripotent Stem Cells May Hold Key To Reversing Aging
Wall Street Pit Knowing how blood cells became less functional with age, what they did was provide the mice with induced pluripotent stem (iPS) cells — stem cells that can produce any kind of cell not just blood cells — and the result was nothing short of amazing … |
CBS News |
Gene therapy lets a French teen dodge sickle cell disease
CBS News A French teen who was given gene therapy for sickle cell disease more than two years ago now has enough properly working red blood cells to dodge the effects of the disorder, researchers report. The first-in-the-world case is detailed in Thursday’s New … Sickle cell anemia patient ‘cured’ by gene therapy, doctors sayFOX 61 In a first, gene therapy cures teen with sickle cell diseaseEconomic Times Case Report: Sickle Cell Disease Gene TherapyRare Disease Report BioNews –BBC News –New England Journal of Medicine all 78 news articles » |
|
Remission in one-third of terminal lymphoma patients after gene therapy
BioNews The trial used genetically modified cells taken from the patient’s own immune system, known as CAR-T therapy. After six months, cancer had shrunk by at least half in 82 percent of patients with non-Hodgkin lymphoma. ‘The numbers are fantastic,’ said Dr … |
OncLive |
Novel Study of Next-Generation BCMA-Targeted CAR-Modified T Cells for Multiple Myeloma Opens at MSK
OncLive Chimeric antigen receptor (CAR) T-cell therapy has been developed as a novel strategy whereby the immune system functions as the “drug” against cancer—by taking out a patient’s own T cells from peripheral blood, inserting a so called “vector” in the T … |